An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events

Celregen Therapeutics

Status and phase: Invitation-only; Early Phase 1

Conditions: Pancreatogenic Diabetes Mellitus; T1DM - Type 1 Diabetes Mellitus

Treatments: Drug: CRG002

Study type: Interventional

Funder types: Industry

Identifiers

NCT07503028

CRG002SEIIT

Details and patient eligibility

About

This study is an open-label, single-arm, non-randomized trial designed to evaluate the safety and preliminary efficacy of CRG-002 administered via portal vein infusion or transplantation beneath the anterior rectus sheath in patients with type 1 diabetes mellitus (T1DM) or pancreatogenic diabetes who have hypoglycemia unawareness or severe hypoglycemic events.

Enrollment: 10 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age 18-70 years, any gender.
2. Long-standing type 1 diabetes or pancreatic diabetes.
3. Significant pancreatic islet dysfunction.
4. Hemoglobin A1c within clinically acceptable range.
5. At least 1 hypoglycemic event requiring external intervention within 12 months.
6. Able to comply with intensive glucose management.
7. Agree to use the study-designated monitoring device.
8. Psychologically stable.
9. Full legal capacity.

Exclusion criteria

1. Type 2 diabetes.
2. Body mass index (BMI) > 30 kg/m².
3. Uncontrolled diabetic retinopathy or severe diabetic foot complications.
4. Active infection or positive serology for relevant pathogens.
5. Severe cardiovascular disease.
6. Uncontrolled hypertension.
7. Hematologic disorders affecting HbA1c accuracy.
8. Abnormal liver function.
9. Prior islet transplantation.
10. Renal impairment or insufficient post-transplant recovery.
11. Significant renal impairment.
12. Recent invasive fungal infection.
13. Severe hematologic abnormalities.
14. Coagulopathy.
15. Inadequate contraceptive compliance.
16. Active malignancy.
17. History of substance abuse.
18. Severe gastrointestinal/malabsorption disorders.
19. Severe psychiatric disorder.
20. Participation in other clinical trials within 6 months.
21. Live-attenuated vaccine received within 2 months prior to enrollment.
22. Inability to undergo standard imaging.
23. Other factors deemed unsuitable by investigator.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Experimental group

Experimental group

Description:

CRG002

Treatment:

Drug: CRG002